2024.12.22 (일)

  • 맑음속초3.3℃
  • 맑음-3.5℃
  • 맑음철원-3.8℃
  • 맑음동두천-1.7℃
  • 맑음파주-1.8℃
  • 맑음대관령-7.2℃
  • 맑음춘천-1.2℃
  • 구름많음백령도1.8℃
  • 맑음북강릉2.9℃
  • 맑음강릉1.9℃
  • 맑음동해3.2℃
  • 맑음서울-0.4℃
  • 맑음인천-0.9℃
  • 맑음원주-2.4℃
  • 눈울릉도1.3℃
  • 맑음수원-0.7℃
  • 맑음영월-2.1℃
  • 맑음충주-1.9℃
  • 맑음서산1.3℃
  • 맑음울진3.0℃
  • 맑음청주0.0℃
  • 맑음대전1.5℃
  • 맑음추풍령-1.8℃
  • 맑음안동-0.5℃
  • 맑음상주0.2℃
  • 맑음포항3.0℃
  • 맑음군산1.5℃
  • 맑음대구1.8℃
  • 맑음전주1.1℃
  • 맑음울산3.2℃
  • 맑음창원3.7℃
  • 구름조금광주2.6℃
  • 맑음부산4.0℃
  • 맑음통영5.4℃
  • 흐림목포2.5℃
  • 맑음여수2.9℃
  • 흐림흑산도4.7℃
  • 구름조금완도5.0℃
  • 구름많음고창2.2℃
  • 맑음순천1.2℃
  • 맑음홍성(예)1.3℃
  • 맑음-0.3℃
  • 흐림제주5.6℃
  • 흐림고산5.8℃
  • 구름조금성산6.3℃
  • 구름조금서귀포9.9℃
  • 맑음진주5.0℃
  • 맑음강화-1.2℃
  • 맑음양평-1.0℃
  • 맑음이천-0.5℃
  • 맑음인제-3.5℃
  • 맑음홍천-2.5℃
  • 맑음태백-2.3℃
  • 맑음정선군-3.1℃
  • 맑음제천-3.3℃
  • 맑음보은-1.4℃
  • 맑음천안-0.4℃
  • 맑음보령2.2℃
  • 맑음부여1.8℃
  • 맑음금산0.7℃
  • 맑음0.4℃
  • 맑음부안3.0℃
  • 맑음임실-0.1℃
  • 맑음정읍1.3℃
  • 맑음남원0.5℃
  • 맑음장수-2.1℃
  • 구름조금고창군2.2℃
  • 흐림영광군1.7℃
  • 맑음김해시4.2℃
  • 맑음순창군0.9℃
  • 맑음북창원3.7℃
  • 맑음양산시5.9℃
  • 맑음보성군4.1℃
  • 구름많음강진군4.3℃
  • 맑음장흥3.9℃
  • 구름많음해남4.9℃
  • 맑음고흥4.0℃
  • 맑음의령군5.5℃
  • 맑음함양군1.9℃
  • 맑음광양시3.9℃
  • 흐림진도군3.6℃
  • 맑음봉화-0.7℃
  • 맑음영주-2.7℃
  • 맑음문경-1.3℃
  • 맑음청송군-0.4℃
  • 맑음영덕0.7℃
  • 맑음의성0.9℃
  • 맑음구미1.7℃
  • 맑음영천1.6℃
  • 맑음경주시2.5℃
  • 맑음거창2.1℃
  • 맑음합천4.9℃
  • 맑음밀양4.5℃
  • 맑음산청2.4℃
  • 맑음거제4.7℃
  • 맑음남해4.1℃
  • 맑음4.8℃
기상청 제공
Shoppy 로고
Cancellation of remaining publicly held registered shares of Vifor Pharma AG
  • 해당된 기사를 공유합니다

Cancellation of remaining publicly held registered shares of Vifor Pharma AG

Last trading day of Vifor registered shares: 22 December 2022
Delisting date of Vifor registered shares: 23 December 2022

Regulatory News:

AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR

Vifor Pharma AG (“Vifor”) announced today that the Commercial Court St. Gallen has cancelled (kraftlos erklärt) all remaining publicly held registered shares of Vifor with a nominal value of CHF 0.01 each (each a “Vifor Share”). The Commercial Court's decision has become legally effective (rechtskräftig) and is published in the Swiss Official Gazette of Commerce (Schweizerisches Handelsamtsblatt; SHAB) by the Commercial Court.

Vifor further announced today that SIX Exchange Regulation AG has determined the last trading day and the delisting date of the Vifor Shares at and from SIX Swiss Exchange as follows:

Last trading day: 22 December 2022

Delisting date: 23 December 2022

As a result of the cancellation of the remaining publicly held Vifor Shares, each holder of cancelled Vifor Shares is entitled to a compensation of USD 179.25 in cash per cancelled Vifor Share. The envisaged settlement date for payment of such compensation against delivery of the cancelled Vifor Shares is 28 December 2022.

About CSL Vifor

CSL Vifor is a global partner of choice for pharmaceuticals and innovative, leading therapies in iron deficiency, dialysis and nephrology & rare disease. We specialize in strategic global partnering, in-licensing and developing, manufacturing and marketing pharmaceutical products for precision healthcare, aiming to help patients around the world lead better, healthier lives. Headquartered in St. Gallen, Switzerland, CSL Vifor also includes the joint company Vifor Fresenius Medical Care Renal Pharma (with Fresenius Medical Care).

The parent company, CSL (ASX:CSL; USOTC:CSLLY), headquartered in Melbourne, Australia, employs 30,000 people and delivers its lifesaving therapies to people in more than 100 countries. For more information about CSL Vifor visit, www.cslvifor.com.

Forward-Looking Statements

This announcement may contain statements that constitute forward-looking statements. The words “anticipate”, “believe”, “expect”, “estimate”, “aim”, “project”, “forecast”, “estimate”, “risk”, “likely”, “intend”, “outlook”, “should”, “could”, “would”, “may”, “will”, “continue”, “plan”, “probability”, “indicative”, “seek”, “target”, “plan” and other similar expressions are intended to identify forward-looking statements.

Any such statements, opinions and estimates in this announcement speak only as of the date hereof and are based on assumptions and contingencies subject to change without notice, as are statements about market and industry trends, projections, guidance and estimates. Forward-looking statements are provided as a general guide only. The forward-looking statements in this announcement are not indications, guarantees or predictions of future performance and involve known and unknown risks, uncertainties and other factors, many of which are beyond the control of CSL and Vifor and their officers, employees, agents and advisors, and may involve significant elements of subjective judgement and assumptions as to future events which may or may not be correct, and may cause actual results to differ materially from those expressed or implied in such statements. You are strongly cautioned not to place undue reliance on forward-looking statements.

This announcement is not a financial product or investment advice, a recommendation to acquire or sell securities or accounting, legal or tax advice. It does not constitute an invitation or offer to apply for securities. It has been prepared without taking into account the objectives, financial or tax situation or needs of individuals. Before making an investment decision, prospective investors should consider the appropriateness of the information having regard to their own objectives, financial and tax situation and needs and seek legal and taxation advice appropriate for their jurisdiction. CSL and Vifor are not licensed to provide financial product advice in respect of an investment in securities.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221213005876/en/

언론연락처: CSL Vifor Media Contact Thomas Hutter Mobile: +41 79 957 96 73 Investor Contact CSL Limited Steve McKeon Associate Director, Investor Relations Mobile +61 402 231 696 Switzerland / Europe Martin Meier-Pfister (IRF) + 41 432 448 140

이 뉴스는 기업·기관·단체가 뉴스와이어를 통해 배포한 보도자료입니다.




포토

 
모바일 버전으로 보기